Home Cart Sign in  
Chemical Structure| 1613028-81-1 Chemical Structure| 1613028-81-1

Structure of SR9243
CAS No.: 1613028-81-1

Chemical Structure| 1613028-81-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SR9243 is a LXR inverse agonist that induces LXR-corepressor interaction and shows anticancer activity and selectively targets the warburg effect and lipogenesis.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SR9243

CAS No. :1613028-81-1
Formula : C31H32BrNO4S2
M.W : 626.62
SMILES Code : BrC1=CC(CCN(S(C2=C(C)C=C(C)C=C2C)(=O)=O)CC(C=C3)=CC=C3C4=CC(S(=O)(C)=O)=CC=C4)=CC=C1
MDL No. :MFCD29049514
InChI Key :FYQFEJFTCLKXTQ-UHFFFAOYSA-N
Pubchem ID :76073169

Safety of SR9243

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
SR9243 is a liver-X-receptor (LXR) inverse agonist that induces LXR-corepressor interaction[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 10 µM 2 hours pretreatment Inhibited the expression of LXRα and ABC transporters, partially suppressed the lipid-lowering effect induced by SR9243 J Cell Mol Med. 2020 Mar;24(6):3384-3398.
RAW 264.7 cells 10 µM 2 hours pretreatment Inhibited the expression of LXRα and ABC transporters, partially suppressed the lipid-lowering effect induced by SR9243 J Cell Mol Med. 2020 Mar;24(6):3384-3398.
HT-29 CD133+ cells 25–200 nM 24, 48, 72 hours To evaluate the effect of SR9243 on CSC viability, results showed SR9243 reduced CSC survival in a dose-dependent manner. Cancer Cell Int. 2021 Feb 10;21(1):100.
ACHN cells 178.2 nM 48 hours Inhibited cell proliferation and induced apoptosis 2019 May 28;10(6):416. doi: 10.1038/s41419-019-1654-6.
786-O cells 51.6 nM 48 hours Inhibited cell proliferation and induced apoptosis 2019 May 28;10(6):416. doi: 10.1038/s41419-019-1654-6.
LMH cells 5 to 40 µM 72 hours SR9243 treatment significantly decreased the transcript and protein expression levels of LXR-α in FAdV-4-infected cells, reducing the number of oil droplets and the accumulation of lipogenic genes. J Virol. 2021 Feb 24;95(6):e01938-20.
Lung cancer cells (HOP-62 and NCI-H23) 15-104 nM SR9243 significantly inhibited cancer cell viability and induced apoptotic cell death Cancer Cell. 2015 Jul 13;28(1):42-56.
Colorectal cancer cells (SW620 and HT29) 15-104 nM SR9243 significantly inhibited cancer cell viability and induced apoptotic cell death Cancer Cell. 2015 Jul 13;28(1):42-56.
Prostate cancer cells (PC3 and DU-145) 15-104 nM SR9243 significantly inhibited cancer cell viability and induced apoptotic cell death Cancer Cell. 2015 Jul 13;28(1):42-56.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice 786-O cell xenograft model Intraperitoneal injection 60 mg/kg 42 days Inhibited tumor growth 2019 May 28;10(6):416. doi: 10.1038/s41419-019-1654-6.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.60mL

0.32mL

0.16mL

7.98mL

1.60mL

0.80mL

15.96mL

3.19mL

1.60mL

References

 

Historical Records

Categories